NEW YORK (GenomeWeb) – Canadian molecular diagnostics firm GenePOC said today that Cardinal Health will be the exclusive distributor of its revogene instrument and associated assays in the US.
The revogene instrument is a portable, qPCR-based molecular diagnostics instrument that runs point-of-care tests. Earlier this month, the US Food and Drug Administration cleared for marketing the instrument along with the GenePOC GBS LB assay for detecting Group B streptococcus.
"We are confident that this new partnership will support us in making a real difference in the diagnosis of infectious diseases by being closer to the patient," GenePOC CEO Patrice Allibert said in a statement. "We further believe this distribution agreement will pave the way for GenePOC to become a key molecular testing player in the mid-size molecular lab, the satellite lab, and all the way into the point-of-care market."
GenePOC is based in Québec and is part of the Debiopharm Group of companies.